TG Therapeutics: 3 Key Takeaways for Long-Term Investors

Detailed summary

Single-dose IV initiation could remove a second clinic visit, but it remains to be seen whether that convenience translates into demand before 2027.

On its third-quarter 2026 earnings call, held on Nov. 9, 2026, TG Therapeutics (NASDAQ:TGTX) raised its full-year 2026 global revenue guidance to $1 billion. Commercial momentum for BRIUMVI, its intravenous (IV, meaning infused into a vein) antibody therapy targeting B cells for relapsing multiple sclerosis (MS, a chronic nervous system disease), is generating operating cash flow to fund pipeline expansion. Long-term investors are watching how management leverages this commercial base into new formulations and indications. Three things management said stand out.

The company raised its full-year outlook as expanding prescriber adoption drove U.S. BRIUMVI revenue up 52% year over year. Higher sales volume provides operating leverage, turning top-line growth into cash flow that funds broader clinical development.

Self-administered treatments account for roughly 35% of new anti-CD20 therapy starts. Adding a quarterly subcutaneous (subcu, injected under the skin) option allows TG Therapeutics to capture patients who prefer home administration without replacing its existing IV business.

Management plans to simplify initiation by combining two separate starting infusions into a single session. Eliminating the second visit enhances convenience for patients and medical centers, which management expects will create demand tailwinds in the second half of 2027.

Third-quarter U.S. net product revenue reached $233 million, and management is not hiding its satisfaction as expected fourth-quarter momentum pushes the annualized run rate above $1 billion. Expanding hospital adoption, high persistence, and a growing pool of treatment-naive patients reinforce commercial scale while clinical trials explore progressive MS.

With patent protection extending into the mid-2040s and $557 million in cash and investments, TG Therapeutics retains financial flexibility to fund pipeline progress alongside share repurchases.

The Motley Fool Stock Advisor analyst team just identified what they believe…

Con…

Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.